Zero Gravity Solutions
Pedro Lichtinger serves as the Chairman and CEO of Starton Therapeutics since March 2017, where strategic leadership has driven the company's growth in proprietary transdermal technology for cancer treatment. Previously, Lichtinger held roles as President and CEO at Asterias Biotherapeutics, where alliances were formed for innovative therapies, and at Optimer Pharmaceuticals, leading the successful market launch of Dificid. Significant contributions also include overseeing the Global Primary Care Business Unit at Pfizer, managing $23 billion in revenue, and spearheading initiatives in both animal health and human health sectors. Lichtinger's extensive experience in the pharmaceutical and biotechnology industries is supported by an MBA from The Wharton School and a BSC in Engineering from UNAM.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Zero Gravity Solutions
Welcome to Zero Gravity Solutions, Inc.'s page, which will provide updates on the progress and development of our company as well as timely, related issues and media regarding various aspects that are shaping the space industry and the need for the sol...